BlackRock
JSPR icon

BlackRock’s Jasper Therapeutics JSPR Stock Holding History

BlackRock’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$71.4K Sell
169,627
-72,434
-30% -$54.2K ﹤0.01% 5098
2026
Q1 		$212K Buy
242,061
+5,837
+2% +$8.1K ﹤0.01% 4751
2025
Q4 		$432K Buy
236,224
+31,292
+15% +$62.8K ﹤0.01% 4515
2025
Q3 		$488K Sell
204,932
-20,673
-9% -$62.7K ﹤0.01% 4459
2025
Q2 		$1.25M Sell
225,605
-562,000
-71% -$2.77M ﹤0.01% 4184
2025
Q1 		$3.39M Sell
787,605
-20,481
-3% -$136K ﹤0.01% 3798
2024
Q4 		$17.3M Buy
808,086
+8,058
+1% +$168K ﹤0.01% 3131
2024
Q3 		$15M Buy
800,028
+107,048
+15% +$2.13M ﹤0.01% 3204
2024
Q2 		$15.7M Buy
692,980
+499,558
+258% +$12M ﹤0.01% 3128
2024
Q1 		$5.68M Buy
193,422
+61,025
+46% +$1.08M ﹤0.01% 3616
2023
Q4 		$1.04M Buy
132,397
+319
+0.2% +$2.14K ﹤0.01% 4239
2023
Q3 		$925K Sell
132,078
-1,157
-0.9% -$14.1K ﹤0.01% 4269
2023
Q2 		$1.83M Buy
133,235
+7,583
+6% +$113K ﹤0.01% 4086
2023
Q1 		$2.27M Buy
125,652
+104,240
+487% +$1.93M ﹤0.01% 3997
2022
Q4 		$103K Buy
21,412
+109
+0.5% +$730 ﹤0.01% 5035
2022
Q3 		$168K Sell
21,303
-504
-2% -$9.22K ﹤0.01% 5023
2022
Q2 		$421K Buy
21,807
+4,850
+29% +$138K ﹤0.01% 4827
2022
Q1 		$603K Buy
16,957
+8
+0% +$361 ﹤0.01% 4828
2021
Q4 		$1.33M Buy
+16,949
New +$1.59M ﹤0.01% 4564

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock's JSPR Position: Q2 2026 in Review

BlackRock reduced its Jasper Therapeutics (JSPR) stake by 30% in Q2 2026, selling an estimated $54.2K and leaving 169,627 shares worth $71.4K. The position accounts for ﹤0.01% of the portfolio, ranked #5098.

BlackRock first reported a position in JSPR in Q4 2021 and has held it in 19 quarters since. The position peaked at $17.3M in Q4 2024. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

  • BlackRock held 169,627 shares of Jasper Therapeutics worth $71.4K as of Q2 2026.
  • BlackRock sold 72,434 Jasper Therapeutics shares in Q2 2026, an estimated $54.2K.
  • Jasper Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5098 holding.
  • BlackRock first reported a position in Jasper Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • BlackRock's Jasper Therapeutics position peaked at $17.3M in Q4 2024.
  • 45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.